Reduction of sympathetic outflow by central administration of L-DOPA, dopamine and norepinephrine

Comparison of noradrenaline, dopamine and serotonin in mediating the tachycardic and thermogenic effects of methamphetamine in the ventral medial prefrontal cortex

Methamphetamine (METH) is a psychostimulant that disrupts monoaminergic neurotransmission to evoke profound behavioral and physiological effects. Rapidly distributing to forebrain regions to increase synaptic concentrations of three monoamines (dopamine (DA), serotonin (5-HT) and noradrenaline (NA)), the medial prefrontal cortex (mPFC) is important in METH-altered behavioral and psychological profiles. Activation of the ventral mPFC can modify physiological variables, however, METH-evoked autonomic changes from this region are unknown. Therefore, the aim of this study was to characterize the respiratory, metabolic and cardiovascular effects of microinjection of METH, DA, 5-HT and NA into the ventral mPFC in urethane-anesthetized Sprague-Dawley rats. METH and NA microinjection evoked dose-related increases in heart rate, interscapular brown adipose tissue temperature and expired CO2, a pattern of response characteristic of non-shivering thermogenesis. NA and 5-HT microinjection elicited pressor and depressor responses, respectively, with matching baroreflex adjustments in sympathetic nerve activity while METH and DA evoked no change in vasomotor outflow. Low doses of METH and DA may evoke respiratory depression. These data suggest that METH's actions in the ventral mPFC, likely via adrenergic receptors, evoke non-shivering thermogenesis which may contribute to the increased body temperature and tachycardia seen in those that abuse METH.

Activation of noradrenergic mechanism attenuates glutamate-induced vasopressor responses in the pons and medulla of cats in vivo

1. Using anesthetized cats, the authors examined the noradrenergic modulation of the glutamate induced pressor and depressor responses in various brainstem areas, including pontine gigantocellular tegmental field (FTG), dorsomedial medulla (DM), rostral ventrolateral medulla (RVLM), and caudal ventrolateral medulla (CVLM). 2. Unilateral microinjection of L-glutamate (Glu, 3 nmol in 30 nL saline) into FTG, DM and RVLM produced an increase in systemic arterial pressure (SAP) and a decrease in heart rate (HR), while into CVLM produced decreases of SAP and HR. 3. Application of norepinephrine (NE) into the pressor areas (0.05 to 5 nmol) did not alter the resting SAP and HR, but significantly attenuated the Glu-induced pressor response with an order of potency: FTG > DM > RVLM. In the depressor CVLM, NE alone produced a dose-dependent decrease of resting SAP and HR, but did not affect the Glu-induced depressor responses. 4. The involvement of different adrenoceptor subtypes was further investigated by application of selective adrenoceptor agonists including phenylephrine (alpha1), clonidine (alpha2), and isoproterenol (beta). Responses to these agonists are similar to those elicited by NE, except that only alpha-adrenoceptor agonists could antagonize the Glu-induced pressor responses of the RVLM. 5. Our observations indicate that NE not only inhibits the pressor mechanisms in various brainstem areas but also elicits a direct depressor response in CVLM. These findings also suggest that NE acts more likely a neurotransmitter, rather than a modulator, in the CVLM.

Central pressor effect of parathyroid hormone-related protein in conscious rats

Although the parathyroid hormone-related protein gene is widely expressed in the central nervous system, the role of this protein in blood pressure is unknown. This article examines whether parathyroid hormone-related protein is involved in the central regulation of blood pressure. An intraventricularly injected solution of parathyroid hormone-related protein elicited a dose-dependent increase of mean arterial pressure accompanied by a decrease of heart rate in conscious Sprague-Dawley rats. An anti-parathyroid hormone-related protein monoclonal antibody, given in an intraventricularly injected solution, blocked the pressor effect of parathyroid hormone-related protein. Furthermore, this pressor effect of parathyroid hormone-related protein was also abolished after pretreatment by intravenous administration of either hexamethonium bromide or doxazosin mesylate. These results suggest that central parathyroid hormone-related protein is implicated in the regulation of blood pressure, and that this effect may be mediated through sympathetic activation.

Regulation of blood pressure with calcium-dependent dopamine synthesizing system in the brain and its related phenomena

The effects of calcium on blood pressure regulation remain controversial. Although the mechanism by which calcium increases blood pressure when it is given intravenously and acutely has been elucidated, that by which calcium reduces blood pressure when it is supplemented chronically and slightly through daily diet is unclear. From a number of animal experiments concerning the effects of calcium on blood pressure, we believe that calcium ions have two separate roles in the regulation of blood pressure through both central and peripheral systems: (1) calcium ions reduce blood pressure through a central, calcium/calmodulin-dependent dopamine-synthesizing system and (2) calcium ions increase blood pressure through an intracellular, calcium-dependent mechanism in the peripheral vasculature. These concepts were applied to elucidate the mechanisms underlying hypertension in spontaneously hypertensive rats (SHR) and changes in blood pressure in other experimental animals, and the following conclusions were reached. The decrease of the serum calcium level in spontaneously hypertensive rats (SHR) causes a decrease in calcium/calmodulin-dependent dopamine synthesis in the brain. The subsequent low level of brain dopamine induces hypertension. The increase in susceptibility to epileptic convulsions and the occurrence of hypertension in epileptic mice (El mice) may be linked through a lowering of calcium-dependent dopamine synthesis in the brain, and epilepsy and hypertension may be associated. Exercise leads to increases in calcium-dependent dopamine synthesis in the brain, and the increased dopamine levels induce physiological changes, including a decrease in blood pressure. Cadmium which is not distinguished from calcium by calmodulin, activates calmodulin-dependent functions in the brain, and increased dopamine levels may decrease blood pressure. In this report, our studies are considered in light of reports from many other laboratories.

Enhanced depressor effect of centrally administered high-calcium solution in salt-loaded experimental hypertension

The depressor effect by oral calcium supplementation is known to be more pronounced in salt-dependent than in renin-dependent hypertension. This study was conducted to investigate the role of central calcium on two different pathophysiologic subtypes of experimental hypertension; (a) salt-dependent, deoxycorticosterone acetate-salt hypertensive rats (DOCA), and (b) renin-dependent, 2-kidney, 1 clip (2-K, 1C) hypertensive rats. In DOCA (n = 10), high-calcium solution (Ca+2, 65.2 mM, 10 microl) given centrally (i.c.v.) elicited a marked decrease in mean blood pressure (MBP; 170 +/- 4 to 138 +/- 5 mm Hg, p < 0.01) with a decrease in heart rate (HR; 390 +/- 18 to 344 +/- 17 beats/min, p < 0.05) lasting for 40 min. In 2-K, 1C (n = 10), high-Ca2+ i.c.v. showed a lesser decrease in MBP (178 +/- 4 to 171 +/- 5 mm Hg) and HR (419 +/- 10 to 395 +/- 12 beats/min) with shorter duration (for 20 min) than in DOCA. This significant depressor and bradycardic response to Ca2+ i.c.v. observed in DOCA was dose dependent at Ca2+ concentrations between 65.2 and 130.4 mM. In DOCA, high Ca2+ i.c.v. reduced the plasma noradrenaline (Nad) concentration significantly (479 +/- 81 to 319 +/- 62 pg/ml, p < 0.05). These results suggest that central Ca2+ plays a more important role in regulating sympathetic nerve activity and BP in salt-dependent than in renin-dependent experimental hypertension.

Centrally administered calcium increases the maximum vagal activation of baroreceptor reflex control of heart rate in spontaneously hypertensive rats

Baroreceptor reflex control of heart rate (HR) was examined before and 15 min after intracerebroventricular infusion (i.c.v.) of 10 microliters of high-Ca2+ solution (Ca2+, 16.3 mM) in conscious spontaneously hypertensive (SHR) and Wistar-Kyoto rats (WKY). The slope of the individual regression line of the relation between reflex HR changes (delta HR) and changes in mean arterial pressure (delta MAP) produced by bolus injections of phenylephrine or sodium nitroprusside (delta HR/delta MAP; beats/min/ mm Hg) for bradycardia was significantly less in SHR (-0.60 +/- 0.30; n = 10) than in WKY (-1.78 +/- 0.27; n = 10; p < 0.01) at baseline. The slope increased in SHR during administration of high Ca2+ to -1.39 +/- 0.17 (p < 0.01) but not in WKY: In contrast, no significant changes were observed for the reflex tachycardia both in SHR (n = 7) and WKY (n = 10). Further, we analyzed sigmoidal MAP-HR reflex curves in SHR with i.c.v. of either high Ca2+ (n = 6) or artificial cerebrospinal fluid (aCSF; n = 5). Administration of high Ca2+ reduced the bradycardic plateau and increased HR range without changes in average gain. Our results suggest a modulatory role for central Ca2+ in the baroreceptor reflex control of HR in SHR.

Central alpha 1-adrenoceptors mediate the pressor response to intracerebroventricular injection of noradrenaline in unanesthetized rats

The intracerebroventricular (i.c.v.) administration of noradrenaline (NA) caused dose-dependent blood pressure increases in unanesthetized rats with an ED50 of 35 nmol. Similar pressor responses were observed after the i.c.v. injection of the more selective alpha 1-agonists ST-91, methoxamine and phenylephrine with ED50 of 60, 155 and 575 nmol, respectively. The maximal pressor response was 57 +/- 3 mmHg. No tachyphylaxis was observed when injections of 37.5 nmol of NA was i.c.v.-injected at an interval of 24 hr. No significant differences were observed in the plasma content of NA and adrenaline at the peak of the pressor response to i.c.v.-injected NA when compared to i.c.v. injections of saline. The pressor effects of NA were blocked by the i.c.v. pretreatment with prazosin or yohimbine with ID50 of 0.9 and 29 nmol, respectively. Prazosin was 32-fold more potent than yohimbine in blocking the effect of i.c.v. NA, suggesting the involvement of alpha 1-adrenoceptors in the central mediation of the pressor response to NA. Intravenous injections of 13 nmol of prazosin or 90 nmol of yohimbine did not affect the pressor response to i.c.v. NA, further indicating the central nervous system nature of the response.

Augmented central pressor action of magnesium in SHR

This study attempted to determine whether central magnesium (Mg) influences the regulation of blood pressure (BP). An intracerebroventricular (icv) injection of a high Mg2+ solution (190.0 mEq/L, 10 microL), made by adding MgC12 to artificial cerebrospinal fluid, increased the mean BP in both conscious spontaneously hypertensive rats (SHR; n = 17, p < 0.001) and Wistar Kyoto rats (WKY; n = 8, p < 0.005). Spontaneously hypertensive rats showed a greater pressor response than WKY (+11.7 +/- 0.9 mm Hg versus +3.5 +/- 1.1 mm Hg, p < 0.001). This pressor response to Mg2+ given icv was dose-dependent in the range of Mg2+ concentration between 47.5 and 190.0 mEq/L in SHR. A high Mg2+ solution (190.0 mEq/L), made by adding MgSO4 given icv, also increased the mean BP in SHR (n = 7, p < 0.001) and WKY (n = 6, p < 0.01), whereas the high osmolarity solution (340 mOsm/kg H2O) given icv did not change the mean BP in either SHR or WKY. Also administered was a high Mg2+ solution icv after either hexamethonium bromide (Hx; 50 mg/kg intravenously) or arginine vasopressin antagonist (aAVP, (CH2)5Tyr(Me)AVP, 30 micrograms/kg i.v.). The pressor response to the high Mg2+ solution was abolished by arginine vasopressin antagonist both in SHR and WKY, although it was not canceled by Hx. A high Mg2+ solution administered icv caused a 3.5-fold increase in plasma arginine vasopressin concentration in SHR (n = 5, p < 0.001).(ABSTRACT TRUNCATED AT 250 WORDS)

Depressor effect of intraventricular administration of calcium on spontaneously hypertensive rats

The role of central Ca2+ in the regulation of blood pressure (BP) was investigated in conscious spontaneously hypertensive (SHR) and Wistar-Kyoto rats (WKY). Ten microliters of a high Ca2+ solution (Ca2+: 32.6 mM) administered intracerebroventricularly (i.c.v.) decreased the mean arterial pressure (MAP) for more than 20 min in SHR (n = 7, P < 0.005), while no change of MAP was observed in the WKY (n = 6). This depressor response to Ca2+ i.c.v. was dose-dependent at Ca2+ concentrations between 16.3 and 65.2 mM. We also investigated the effect of high Ca2+ i.c.v. in SHR after pretreatment with Ca2+ channel blockers, diltiazem (60 micrograms/10 microliters) or nisoldipine (4, 8, 16 and 32 micrograms/10 microliters), administered i.c.v., the autonomic ganglion blocker, hexamethonium (50 mg/kg), administered i.v. and alpha-methyl-p-tyrosine (100 and 400 micrograms/10 microliters) delivered i.c.v. Pretreatment with i.c.v. diltiazem (n = 8) or nisoldipine (n = 5 for 8 micrograms, n = 6 for 4, 16, 32 micrograms) abolished and/or blunted the decrease of MAP due to high Ca2+. Hexamethonium administered i.v. (n = 6) also canceled the depressor action of i.c.v. Ca2+. Pretreatment with 100 micrograms of i.c.v. alpha-methyl-p-tyrosine could not prevent the depressor action of i.c.v. Ca2+; however, 400 micrograms of alpha-methyl-p-tyrosine administered i.c.v. abolished the effect of i.c.v. Ca2+. Furthermore Ca2+ channel blockers administered i.c.v. in themselves increased MAP in SHR (P < 0.05). These results suggest that central Ca2+ is involved in the central regulation of BP in SHR. This effect may be mediated through changes in sympathetic activity.

Central neural mechanism contributing to attenuation of angiotensin II-induced hypertension in rats on dietary calcium supplementation

The effect of dietary calcium (Ca) supplementation on blood pressure (BP) and the central nervous system (CNS) mechanism underlying this effect were studied in angiotensin II (Ang II)-induced hypertensive rats. The effects of dietary Ca (0.5, 2, 4%) on systolic blood pressure (SBP), ionized Ca concentration (Ca++) in cerebrospinal fluid (CSF) and central norepinephrine (NE) turnover were investigated in male Wistar rats receiving subcutaneous infusion of Ang II (100 ng/min). Central NE turnover was studied by measuring 3-methoxy-4-hydroxyphenylglycol (MHPG) concentration in CSF with multiple electrode liquid chromatography. Ang II significantly increased SBP, and dietary Ca dose-dependently attenuated the increase. SBP inversely correlated with Ca++ and MHPG in CSF. Intracerebroventricular injection of CaCl2 more markedly reduced BP in Ang II-treated rats than that in control rats. These results suggest that modulation of central NE turnover possibly caused by the increase in CNS Ca++ is involved in the anti-hypertensive mechanism of dietary Ca supplementation in Ang II-induced hypertensive rats.

Decrease of central dopamine level in the adult spontaneously hypertensive rats related to the calcium metabolism disorder

The metabolism of calcium and brain dopamine in spontaneously hypertensive rats (SHR) after the development of hypertension was investigated as a possible model for the hypertension mechanism. Serum calcium level in SHR was lower than that in the normotensive control. Wistar Kyoto rats (WKY, the parent strain of SHR). Conversely, bone calcification of SHR was higher than that in WKY. Possible mechanisms for the lower serum calcium level seen in SHR include a decrease in the availability of calcium from bone. The immunohistochemical dopamine levels in the neostriatum and nucleus accumbens in SHR were lower than those in WKY. In these regions, the dopamine level was increased by the intraventricular administration of CaCl2 through a central, calmodulin-dependent system. This study suggests, based upon previous pharmacological studies, that the decrease of the serum calcium level in SHR causes a decrease in central, calcium-calmodulin-dependent dopamine synthesis and a subsequent low level of dopamine in the brain that produces an increase in blood pressure through functions of cerebral dopaminergic neurons and peripheral sympathetic nerves. Our results suggest that this could be one of the mechanisms of hypertension in SHR.

Contribution of the central interaction between calcium and sodium to hemodynamic regulation in spontaneously hypertensive rats

The contribution of the central interaction between calcium and sodium to hemodynamic regulation was assessed in spontaneously hypertensive rats (SHRs) and Wistar-Kyoto (WKY) rats. The effect of a high calcium solution (Ca2+, 130 mg/dl, 10 microliters) infused into the cerebral ventricle (i.c.v.) on hemodynamic responses induced by a high sodium solution (Na+, 1,000 mEq/1, 10 microliters) i.c.v. and the mechanism by which high Ca2+ affects the hemodynamic responses induced by high Na+ i.c.v. were studied. High Na+ i.c.v. induced a pressor response with tachycardia in the SHRs, but induced a pressor response with reflex bradycardia in the WKYs. Prior treatment with high Ca2+ i.c.v. attenuated the pressor response induced by high Na+ i.c.v. (+55.6 +/- 4.4 to +33.1 +/- 3.2 mmHg, P < 0.01) and restored reflex bradycardia (+86.4 +/- 7.7 to -26.7 +/- 7.6 bpm, P < 0.01) in SHRs. Whereas prior treatment with high Ca2+ i.c.v. attenuated the pressor response (+35.7 +/- 2.0 to +22.2 +/- 4.0 mmHg, P < 0.05), it did not alter the degree of reflex bradycardia (-81.7 +/- 7.1 to -69.2 +/- 120 bpm, n.s.) in WKYs. Ganglionic blockade attenuated the pressor response (+56.9 +/- 3.5 to +42.9 +/- 2.3 mmHg, P < 0.05) and restored reflex bradycardia (+82.1 +/- 10.3 to -65.9 +/- 11.0 bpm, P < 0.01) in SHRs, whereas, inhibition of arginine vasopressin attenuated the pressor response without modification of the tachycardic response.(ABSTRACT TRUNCATED AT 250 WORDS)

Long-term depressor effects of catecholamine neuronal grafts in the third ventricle of the brain in normotensive rats

Neuronal tissue containing A-6 group noradrenalin (NA) neurons of the locus ceruleus, or A-10 group dopamine (DA) neurons of the substantia nigra, was grafted into the third ventricle at the level of the preoptic-anterior hypothalamic region, in normotensive male rats. A significant and long-lasting depressor effect was shown in rats with either graft. In rats with an NA neuron-rich graft, plasma concentrations of arginine-vasopressin (AVP), plasma renin activity (PRA), and corticosterone (CS) decreased significantly, whereas in rats with a DA neuron-rich graft, AVP and PRA concentrations also decreased significantly but CS showed no significant change. Neither NA nor adrenalin in plasma changed significantly in rats with either graft.

Respiratory and circulatory effects of centrally administered phencyclidine in anesthetized dogs

1. Anesthetized dogs were given phencyclidine HCl (PCP) by intracerebroventricular (i.c.v.) injection. 2. Physiological parameters were monitored after consecutive doses of 0.5, 1.0 and 2.0 mg of PCP. 3. Dose-related changes seen, including bradycardia, hypotension and bradypnea, were opposite to those produced by i.v. doses. 4. Single doses of 1.0 or 2.0 mg of PCP confirmed the prior observations, and the latter provided the baseline for further observations on dogs receiving PCP before various i.c.v. pretreatments--atropine, haloperidol, phentolamine or propranolol--in efforts to characterize the central neurotransmitter system(s) involved in the PCP effects.

Cardiovascular reactivity and plasma prolactin response to mental stress in normals and hypertensives

Central dopaminergic activity (CDA) may be involved in blood pressure control as a negative modulator of sympathetic outflow. In this study the plasma PRL changes produced by mental stress (a colour-word conflict test, CWT) were investigated in normals (NT, n.15) and stable hypertensives (HT, n.16) and the PRL response, as a possible index of CDA was correlated to the cardiovascular and the plasma renin activity (PRA) responses as indexes of peripheral sympathetic outflow. A significant (p less than 0.05) slight decrease in mean values of PRL was observed in normals after the CWT but no change was found in hypertensives. No correlation was found between the PRL responses to CWT and the maximal mean arterial pressure changes or the PRA changes whether the groups were considered separately or together. These findings indicates that PRL does not appear to be a reliable index of the CDA involved in blood pressure control.

Blood pressure, plasma and pituitary prolactin responses to bromocriptine in New Zealand genetically hypertensive and normotensive rats

1. The effects on blood pressure (BP), plasma and pituitary prolactin (PRL) of a 13 day intraperitoneal infusion of bromocriptine (BRC) delivered by osmotic minipump were investigated in genetically hypertensive rats (GHR) and their normotensive (NT) controls. 2. In the GHR, the mean BP in the BRC-treated group over the 13 day period of study was significantly lower than in the vehicle-treated group. In the NT rats, the mean BP in the BRC-treated group over the 13 day period was also significantly lower than in the vehicle-treated group. 3. Mean plasma PRL concentration in the GHR and NT rats were comparable. In the GHR, the mean plasma PRL concentration taken on day 13 was significantly lower in the BRC-treated group than in the vehicle-treated group. In the NT rats, the mean plasma PRL concentration taken on day 13 in the BRC-treated group was, however, not significantly different from that in the vehicle-treated group. 4. The mean pituitary PRL content was not significantly different in the GH and NT rats. There was a greater suppression of pituitary PRL content in the BRC-treated GHR than in the BRC-treated NT rats compared with their respective vehicle-treated groups. 5. The results raise the possibility that PRL may have an indirect role in the pathogenesis of the hypertension of the GHR.

Effect of intraventricular administration of calcium and calmodulin antagonist on the blood pressure in the rat

The effect of intraventricular administration of calcium on the mean arterial pressure in the conscious rat was investigated. Biphasic changes of blood pressure, fugitive rapid increment during the first 3 min and gradual lengthy decrement during the next 60 min were observed by the administration of CaCl2 (30 mumol/kg). Both these changes were significant as compared with the control level. On the other hand, the biphasic response of blood pressure by CaCl2 was abolished by the administration of calmodulin antagonist, W-7, or catecholamine synthesizing enzyme inhibitor, alpha-methyltyrosine. These results are discussed on the basis of our calcium-calmodulin-dependent biogenic amine-synthesizing mechanism.

The actions of dopamine on the blood pressure and heart rate of conscious hypertensive rats: evidence for reduced dopaminergic activity in rats of the Japanese strains

The effects of intracerebroventricularly (icv) and intravenously (iv) administered dopamine (DA) on mean arterial pressure (MAP) and heart rate were investigated in conscious spontaneously hypertensive rat (SHR), stroke-prone SHR (spSHR) and normotensive Wistar-Kyoto (WKY) rat of Japanese strains, genetically hypertensive (GHR) and normotensive (NT-NZ) rat of New Zealand strains, Sprague-Dawley (SD) rat, and left renal artery stenosed hypertensive WKY (WKYLRAS) and SD (SDLRAS) rats. Icv DA (0.0125-0.4 mg/kg) caused a linear dose-related decrease in MAP, accompanied by bradycardia in all animals. By contrast, the same doses of DA given iv caused a linear dose-related increase in MAP, accompanied by reflex bradycardia in most groups (except the spSHR, SHR and WKYLRAS where tachycardia occurred to most of the doses employed), indicating that the decrease in MAP following icv DA is centrally-mediated. A "greater" relative hypotensive effect to icv DA was seen in the Japanese hypertensive strains SHR and spSHR compared to the WKY, but not between the New Zealand strains or the renal hypertensive animals. Our data also show that this marked hypotensive responsiveness is not related to the basal MAP, but appears to be strain-specific. It is thus possible that the alleged reduced central dopaminergic activity in the Japanese strains of hypertensive rats may be responsible for exaggerated hypotensive responses observed in these strains.

alpha-Adrenoceptor agonists applied in the area of the nucleus tractus solitarii in the rat: effect of anesthesia on cardiovascular responses

We investigated the blood pressure and heart rate responses to unilateral local application of norepinephrine or clonidine in the area of the nucleus tractus solitarii (NTS) of conscious rats and rats anesthetized by 3 general anesthetics commonly used in cardiovascular research. In the conscious state, microinjection of either substance produced an immediate, sharp increase in blood pressure and decrease in heart rate with a gradual return to baseline over a period of more than 30 min. However, light ether anesthesia, nembutal, or urethane drastically reduced, abolished or even reversed the pressor effect of local microinjection of the same substance. Our results suggest that in conscious rats, the initial effect of alpha agonists in the NTS area is to modulate baroreceptor reflexes towards higher blood pressure levels and that general anesthesia may significantly alter or mask the cardiovascular responses to various experimental manipulations.

Reduced activity of locus coeruleus neurons in hypertensive rats

The influence of blood pressure on locus coeruleus (LC) neuronal activity was investigated in chloral hydrate anesthetized rats. Mean spontaneous firing rate of LC neurons was reduced by 25% in deoxycorticosterone acetate (DOCA-salt) treated Sprague-Dawley rats and by 19% in spontaneously hypertensive rats (SHR) as compared to their corresponding control animals. In acute experiments performed on normotensive rats, peripherally induced blood pressure changes elicited reciprocal changes in cell firing of the majority of LC neurons. The findings suggest that LC may have a role in long-term regulation of blood pressure.

Central and peripheral dopaminergic mechanisms in the cardiovascular actions of pergolide in neurogenic hypertensive dogs

The cardiovascular actions of the dopaminergic ergoline, pergolide were examined in pentobarbital-anesthetized dogs. When administered intravenously (i.v.) to dogs made hypertensive by sino-aortic deafferentation, pergolide produced a sustained reduction in blood pressure, dilatation of the hindlimb vasculature and bradycardia. The antihypertensive action of pergolide in neurogenic hypertensive dogs was converted into a pressor action when it was given to dogs pretreated with i.v. sulpiride or hexamethonium plus atropine. Pergolide caused significant impairment of renal vasoconstriction elicited during stimulation of renal sympathetic nerves but not that caused by exogenous norepinephrine. The inhibitory action of pergolide on renal sympathetic nerve function was antagonized by sulpiride suggesting that pergolide activated presynaptic dopamine receptors. Direct administration of pergolide within the central nervous system via the cisterna magna (i.c.) to normotensive dogs also resulted in hypotension, bradycardia and iliac vasodilatation. The central actions of pergolide were prevented by sulpiride (i.c.) but not by yohimbine (i.c.), which indicates that specific activation of central dopamine receptors was responsible for these actions of pergolide. The antihypertensive, bradycardic and iliac vasodilatory actions of i.v. pergolide in neurogenic hypertensive dogs were significantly attenuated by i.c. sulpiride. It was determined that while this dose of sulpiride antagonized central dopamine receptors, it did not antagonize peripheral presynaptic dopamine receptors. These results suggest that pergolide exerts antihypertensive and bradycardic actions via simultaneous stimulation of dopamine receptors in the brain and on postganglionic sympathetic neurons. While presynaptic dopamine receptor activation contributes to the blood pressure lowering action of pergolide, stimulation of central dopamine receptors appears to be the dominant mechanism by which pergolide elicits the observed antihypertensive and bradycardic effects. Pergolide appears to lower blood pressure by a novel mechanism of action and may offer an additional therapeutic approach for the treatment of hypertension.

The regulation of cardiovascular functions by monoamine neurotransmitters in the brain

The complexity of the central nervous system's influence on cardiovascular integration is underscored by the extensive neural interconnections between the various higher and lower brain structures shown by electrophysiological studies to have an influence on cardiovascular function. Furthermore, complex neural connections exist within each level of cardiovascular integration (for instance, the medullary reticular formation, or the limbic system). The electrophysiological analysis of the integrative aspects of central cardiovascular regulation has been the subject of several reviews (Reis, 1972; Smith, 1974; Calaresu et al., 1975; Oberg, 1976). In recent years, the methodology of analyzing the anatomical neural pathways of central cardiovascular regulation by lesion-degeneration, evoked potential, and fluorescent histochemical procedures, has been improved with the introduction of anterograde and retrograde tracer techniques. The result is the delineation of previously undetected neural interconnections among various brain areas, long known as cardiovascular centres, such as the NTS, the parabrachial nucleus, the paraventricular nucleus of the hypothalamus, the central nucleus of the amygdala, and the bed nucleus of the stria terminalis (Loewy & McKellar, 1980). Undoubtedly the next few years will see major advances in the understanding of the neuroanatomical pathways involved in central cardiovascular control.

Dysfunction of supramedullary alpha-adrenergic mechanisms following sino-aortic denervation in Kyoto Wistar rats

Central alpha-adrenergic mechanisms of blood pressure regulation were investigated by injecting norepinephrine or bradykinin into the carotid input of the cross-circulated head preparations of normotensive Wistar Kyoto rats (WKY). Rats were divided into three groups: sham-operated (sham), carotid sinuses denervated (SD) and carotid sinuses and aortic nerves debuffered (SAD). Norepinephrine, 5 micrograms, produced vasodepression in all rats, accompanied by corresponding decreases in sympathetic nerve activity recorded in some rats. Magnitude of vasodepression was largest in SAD rats. In sham rats, bradykinin, 1 micrograms, produced a biphasic response: initial vasodepression followed by a sustained pressor phase. This was accompanied by corresponding changes in peripheral sympathetic nerve activity recorded in some rats. In both SAD and SD rats bradykinin-induced vasodepression was abolished, while the magnitude of the pressor phase became more prominent. The increase in the pressor phase was greater in SAD than in SD rats. In similar studies of spontaneously hypertensive rats (SHR), responses to both alpha-adrenergic agonist and bradykinin are augmented, suggesting a dysfunction of hypothalamic alpha-adrenergic mechanisms. Since in the present study it has been shown that sino-aortic denervation produces effects similar to those seen in SHR, dysfunction of buffer nerves may account for the deficient central alpha-adrenergic mechanisms in SHR.

Effect of the intracerebroventricular injection of dopamine on blood pressure in the spontaneously hypertensive rat

To examine the role of the central dopaminergic system in blood pressure regulation, dopamine was injected into the cerebral lateral ventricles of conscious, unrestrained spontaneously hypertensive rats (SHR), deoxycorticosterone (DOC)-salt hypertensive rats and Wistar-Kyoto normotensive rats (WKY). Intracerebroventricular (i.c.v.) injection of dopamine produced a significant dose-dependent decrease in blood pressure in the SHR as well as in the WKY and DOC-salt hypertensive rats. However, the SHR were significantly more sensitive than were the other 2 groups of rats. In the SHR, this central depressor effect of dopamine was significantly attenuated by pretreatment with i.c.v. metoclopramide, but not by phentolamine, suggesting that central dopamine receptors rather than alpha-adrenoceptors are involved in the mediation of the actions of dopamine in the brain. These results suggest that the central dopaminergic system plays a more important role in the regulation of blood pressure in the SHR than in the WKY and DOC-salt hypertensive rats.

Prolactin, renin and catecholamines in essential hypertension

In 40 male patients with essential hypertension less than the age of 36 years, the plasma prolactin (PRL), plasma renin activity (PRA) and plasma catecholamines (noradrenaline (NA) and adrenaline (A)) were determined simultaneously. Those levels were significantly increased compared to the levels in 14 age-matched healthy male control subjects. Furthermore, there were significant correlations between the PRL and plasma NA or PRA (p less than 0.05 in each case), and between the PRA and plasma NA (p less than 0.05). However, no significant relationships were observed between systolic or diastolic blood pressure and PRL, plasma NA or PRA. These findings indicate that the central dopaminergic activity is reduced in a number of young adults with essential hypertension, and that in the patients with the reduced central dopaminergic activity, the peripheral sympathetic activity is stimulated and PRA is also increased probably due to the increased peripheral sympathetic activity, and the possibility exists that such changes are related to the development of hypertension.

Inhibition of the activity of sympathetic preganglionic neurones and neurones activated by visceral afferents, by alpha-methylnoradrenaline and endogenous catecholamines

The responses of electrophysiologically identified sympathetic preganglionic neurones (SPGN) and neurones activated by visceral afferents (VA) to iontophoretic application of: (1) the intraneuronal metabolites of alpha-methyl-DOPA (alpha-MD): alpha-methylnoradrenaline (alpha-MNA) and alpha-methyldopamine (alpha-MDA); (2) noradrenaline (NA) and adrenaline (Ad); and (3) N-methyl-beta-hydroxy-phenylethylamine (NMPEA), were tested in the upper and lower segments of the thoracic spinal cord of the cat. alpha-Methylnoradrenaline, NA and Ad had an inhibitory action on the majority of spontaneously firing neurones. Inhibition of the activity of preganglionic neurones and neurones activated by visceral afferents induced by alpha-MNA was usually equal to the effect of NA, but in some neurones alpha-MNA was more potent. The transport numbers of both amines are similar. The alpha adrenoceptor antagonists, thymoxamine, piperoxan and yohimbine, antagonized the inhibitory effects of alpha-MNA in spontaneously-active preganglionic neurones and neurones activated by visceral afferents. Piperoxan antagonized also the inhibitory effects of NA. The inhibitory effect of alpha-MDA was weaker and that of NMPEA was much weaker than that of alpha-MNA and NA. The inhibitory effects of alpha-MNA and NA in the cerveau isolé preparation resembled those observed in anaesthetized animals. In reserpinized cats, with catecholamine levels in brain stem and spinal cord reduced by 98-99%, the inhibitory effects of alpha-MNA were preserved. It is postulated that alpha-MNA modulates the activity of preganglionic neurones and that this action, leading to a decrease in sympathetic output and mediated by alpha 1 and alpha 2 adrenoceptors, could be the most important factor in the antihypertensive effect of alpha-MD. The inhibition of the activity of neurones activated by visceral afferents by alpha-MNA indicates that alpha-MD may also attenuate the response of the central nervous system to the input from the heart and other organs.

The acute effects of amitriptyline, iprindole and trazodone on blood pressure and heart rate in rats

The cardiovascular effects of the tricyclic anti-depressant amitriptyline, a monoamine uptake inhibitor, and iprindole and trazodone, two novel anti-depressants of unknown mechanism, were monitored in urethane anesthetized rats following intravenous (IV) or intracerebroventricular (IVT) injection. Amitriptyline (2 mg IV or 0.25 mg IVT) produced hypotension that might reflect an action of norepinephrine on the anterior hypothalamus. Iprindole (2 mg IV) produced hypertension and (0.25 mg IVT) tachycardia that is consistent with a partial beta-agonist mechanism. Trazodone (1 mg IV or 0.25 mg IVT) produced hypotension and bradycardia that is consistent with the activation of noradrenergic neurons in the anterior hypothalamus perhaps as a result of trazodone acting on presynaptic alpha 2 receptors or on presynaptic serotonin receptors to increase the release of norepinephrine. All three of these anti-depressants have the potential to precipitate cardiovascular complications, particularly in patients with pre-existing cardiovascular abnormalities.

Alpha-Adrenergic and 5-hydroxytryptaminergic receptor stimulants as new antihypertensive drugs, with observations on involvement of opiate receptors

Cardiovascular actions of central alpha-adrenergic and 5-hydroxytryptaminergic stimulants are discussed in terms of overall effects, correlation of various activities, receptor activation and side-effects. The involvement of opiate receptors in their actions is also examined.

Neurophysiology and neuropharmacology of cardiovascular regulation and stress

Evidence has accumulated over the past several years indicating that environmental factors can have a substantial influence on cardiovascular dynamics. It has been hypothesized by many investigators that through these influence environmental stressors may be important to the etiology and maintenance of cardiovascular diseases. Since the nervous system is intimately involved in the regulation of cardiovascular function it may be assumed that environmental influences on cardiovascular dynamics are to a large extent mediated by the nervous system. This assumption is supported by the literature reviewed which indicates that there are many nervous system nuclei and neurotransmitter systems involved in the regulation of cardiovascular dynamics which are also involved in an organisms adjustment to environmental stressors. The conclusion is reached that further multidisciplinary research will reveal underlying neurophysiological and neuropharmacological mechanisms responsible for stress induced cardiovascular disease and lead to new methods of treatment.

Cardiovascular responses to central catecholamines of sinoaortic denervated rats

The characteristic movement-related arterial pressure dips seen in sinoaortic-denervated (SAD) animals suggested they should have enhanced vasodepressor responses to central adrenergic agonists. This was tested by comparing the reductions in mean arterial pressure and heart rate of conscious sham-operated (SO) and SAD rats during injections of norepinephrine (NE) or epinephrine (E) (0.25--16 micrograms) into the fourth cerebral ventricle. NE produced significantly greater maximum vasodepression and, simultaneously, significantly less bradycardia in SAD than SO rats. E, like NE, produced significantly more vasodepression in SADs, but unlike NE, elicited the same magnitude of bradycardia in both groups. The pressures were reduced and the log-dose pressure response curves shifted to the left in SAD rats. These results provide indirect evidence that central sensitivity to intracerebroventricular catecholamines is altered in SAD rats and that the direction of change in sensitivity is divergent for pressure and heart rate.

Augmentation of centrally induced alpha-adrenergic vasodepression in spontaneously hypertensive rats

Central alpha-adrenergic mechanisms for cardiovascular regulation were studied by injecting phenylephrine into a recipient rat whose head was isolated from its body by cross perfusion with a donor rat. Blood pressure increases produced in the donor were accompanied by concurrent reduction of blood pressure and sympathetic nerve activity in the recipient rat's body. These effects were abolished when alpha-adrenergic receptors in the perfused head were blocked with phentolamine. By contrast, intracarotid injections of angiotensin increased blood pressure not only in donor but also in recipient rats. The magnitude of phenylephrine-induced vasodepression was significantly greater in spontaneously hypertensive rats (SHR) than in normotensive or DOCA-salt hypertensive ones. Distribution of radioactive microspheres indicated that carotid arterial blood went mainly to the cerebrum, midbrain, and hypothalamus, with almost negligible amounts going to the lower brainstem. Collectively, our results suggest that centrally administered phenylephrine reduces sympathetic vasomotor tone and blood pressure by acting on alpha-adrenergic receptors located in supramedullary brain areas (possibly in the hypothalamus). In SHR, augmented, vasodepressor responsiveness may be due to reduced brain levels of endogenous norepinephrine that could increase the alpha-adrenergic receptors available.

The use of bromocriptine for testing central dopaminergic reactivity

A single oral intake of 10 mg of Bromocriptine can modify both plasma renin activity (PRA) and arterial blood pressure (BP). The changes in both variables depend on the integrity of the central dopaminergic systems. The parkinsonians whose extrapyramidal symptoms are markedly improved by L-Dopa in association with a decarboxylase inhibitor (IDC) and the untreated parkinsonians are the only patients whose PRA and BP are lowered 1 h after Bromocriptine ingestion. The results obtained in the L-dopa-induced dyskinetic parkinsonians are similar to those obtained in the group of L-Dopa-resistant patients. This points to the paradoxical hypothesis of dopaminergic hyposensitivity in the dyskinetic patients. In spite of the absence of correlation between PRA and BP, it is possible that lowering of BP by Bromocriptine is linked to the parallel decrease of PRA. An increase of the BP may be obtained in the dyskinetic and L-Dopa-resistant groups. These data point to a possible involvement of central dopaminergic systems in some aspects of hypertension.

Experimental hypertension and catecholamine distribution in the rat brain

Hypertension was induced in rats (Hebrew University strain) by three different procedures: (1) deoxycorticosterone acetate (DOCA)--salt treatment; (2) unilateral renal artery clip or (3) chronic salt-loading. Noradrenaline (NA) and dopamine (DA) distribution in different brain areas was assayed following induction of hypertension. NA content increased significantly in various areas: the increase of NA in the pons-medulla was common to all procedures inducing hypertension. NA content increased also in the mesencephalon, the hypothalamus and the rest of the forebrain (DOCA--salt hypertension), in the mesencephalon, the hypothalamus and the cortex (in renal clip hypertension). No significant changes in DA content were observed in any region of the brain following induction of hypertension by the three different methods. In two substrains, selected from the Hebrew University strain, for their respective sensitivity (H) or immunity (N) to hypertension induced by DOCA--salt treatment, there were no significant increases in NA or DA in any part of the brain following DOCA--salt treatment. Comparison of NA concentrations in these strains showed that NA was significantly higher in the pons-medulla of the untreated N strain rats than in the medulla of untreated H strain or in untreated rats of the original strain (Hebrew University). A model is presented suggesting that central NA-containing neurons plays a major role in controlling hypertension.

Cardiovascular responses produced by the injection of dopamine into the cerebral ventricles of the unanaesthetized dog

1 The injection of dopamine (100 to 500 microgram) into the cerebral ventricles (i.c.v.) of 10 unanaesthetized dogs produced a dose-dependent increase in arterial blood pressure and heart rate. The dogs licked, swallowed, sometimes vomited and became sedated. 2 Autonomic ganglion blockade with hexamethonium (10 mg/kg i.v.) abolished cardiovascular responses to i.c.v. dopamine, indicating that dopamine was exerting its effect within the central nervous system. 3 The dopamine receptor antagonists, haloperidol (500 microgram), chlorpromazine (200 micrograms) and ergometrine (500 micrograms), each given i.c.v., sugsequently abolished the cardiovascular responses to dopamine. 4 Pretreatment with either the beta-adrenoceptor antagonist, propranolol (600 microgram) or the alpha-adrenoceptor antagonist, phentolamine (1 mg) given i.c.v. had no significant effect on the response to dopamine. 5 It is suggested that dopamine injected into the cerebral ventricles of the unanesthetized dog causes hypertension and tachycardia by activating central dopamine receptors.

Pharmacological study of a cholinergic mechanism within the rat posterior hypothalamic nucleus which mediates a hypertensive response

In unanesthetized freely moving rats, microinjection of a variety of cholinergic agonists into the posterior hypothalamic nucleus (PHN) consistently produced an elevation in mean arterial pressure (MAP). Experiments were undertaken to pharmacologically characterize this cholinergic mechanism. Microinjection of carbachol (0.1--100 nmol) into the PHN elicited reproducible and dose-related increase in MAP (17--47 mm Hg) and variable changes in heart rate. Similar responses, although longer in onset and duration, were produced by microinjection of the cholinesterase inhibitors, neostigmine, physostigmine and echothiophate. The pressor responses produced by neostigmine and physostigmine, but not by carbachol, were shown to be dependent upon intact stores of acetylcholine in the PHN. Blockade of postsynaptic muscarinic receptors by prior microinjection of atropine abolished the rise in MAP to subsequent injection of cholinergic agonists; however, similar pretreatment with the antinicotinic agent, mecamylamine, was without effect. The peripheral mechanism through which a rise in MAP was produced by cholinergic stimulation of PHN was the sympathetic nervous system since i.v. injection of an alpha-adrenergic blocking agent, phentolamine, attenuated the pressor response to intrahypothalamic injection of carbachol or neostigmine. Adrenal catecholamine release or vasopressin release were not important mechanisms in this regard. From this study we conclude that within the rat PHN there exists a muscarinic, cholinergic mechanism which, upon activation, mediates a rise in MAP through an increase in sympathetic tone.

Plasmatic renin activity in patients treated with L-dopa and inhibitor of dopa decarboxylase (IDC)

Plasmatic renin activity (PRA) was studied in patients receiving L-dopa, together with a decarboxylase inhibitor, at rest times and after periods of physical exertion. Although we can superimpose the results from unrelated Parkinson's disease patients on those of the control group, the results are inversed in stabilized patients (lowered PRA) and dyskinetic patients (increased PRA). There is a definite correlation between the increase in PRA and intensity of the dyskinesia. Dosage is the only other factor differentiating the two groups of Parkinsonians treated. The figures relative to arterial pressure are studied in the various groups.

Effect of l-dopa on sympathetic nerve activity and blood pressure in the spontaneously hypertensive rat

We examined the effect of L-Dopa, after peripheral L-amino acid decarboxylase inhibition, on sympathetic nerve activity (SNA) and blood pressure in spontaneously hypertensive rats (SHR) and in normotensive control rats. L-Dopa reduced SNA in both groups of animals. The SHRs were significantly more sensitive to the depressor effect of L-dopa than were the control animals, the threshold dose for reduction of SNA being 3 mg/kg in the SHR and 15 mg/kg in control rats. Similarly, the magnitude of inhibition of SNA was substantially greater in the SHR than in normotensive rats. The reduction in SNA in the SHR accompanied by a parallel fall in blood pressure. In contrast, blood pressure in control rats did not change significantly, even though SNA was diminished. Studies of the penetration of L-dopa into the cerebral parenchyma revealed that equivalent amounts of the amino acid entered the brains of the two groups of rats. These results suggest that the SHRs are more sensitive to the SNA-inhibiting effects of L-dopa than are normotensive rats. In addition, they confirm our previous suggestion that excessive SNA plays a causative role in the hypertension of the SHR.

The hypertensive response to injection of physostigmine into the hypothalamus of the unanesthetized rat

Microinjection of physostigmine (3-30 nmoles) into the posterior hypothalamic nucleus of freely-moving, unanesthetized rats elicited a dose-related hypertensive response. This effect was significantly reduced by prior central injection of hemicholinium-3. The direct acting cholinergic agonist, carbachol, also evoked an elevation of blood pressure following intrahypothalamic injection; however, this response was unaffected by prior administration of hemicholinium-3.

Changes in rat hind limb vascular resistance following intracerebroventricular drug administration

The right hind limbs of rats (which had previously implanted intraventricular guide cannulae) were isolated from the systemic circulation, but with the nerves to the limb remaining intact, and perfused using a constant output blood pump. Using this preparation, changes in vascular resistance, blood pressure and heart rate were monitored following injection of noradrenaline, phentolamine and propranolol into the lateral cerebral ventricles (i.c.v.) of rats anaesthetised with alpha-chloralose. All three drugs lowered blood pressure. Noradrenaline administered i.c.v. induced a nervously mediated vasocilatation and an insignificant fall in heart rate whereas i.c.v. phentolamine administration was followed by a nervously mediated vasoconstriction in the isolated hind limb and a gradual rise in heart rate. After i.c.v. administration of propranolol there was no evidence of an immediate nervously mediated vasodilatation but heart rate fell significantly. Following i.c.v. phentolamine or propranolol vasodilatation did not occur in the hind limb until after the time taken for circulating blood ro reach the isolated vascular bed. The vasodilatatory and hypotensive responses to i.c.v. noradrenaline were not evident following prior i.c.v. injection of phentolamine. These results indicate the suitability of this preparation for investigations of central actions of other drugs.

L-dopa-induced hypotension: depression of spinal sympathetic neurons by release of 5-hydroxytryptamine

In studies designed to determine the respective functional roles of two bulbospinal monoaminergic pathways to sympathetic preganglionic neurons, both L-dopa and precursors of 5-HT depressed transmission through excitatory spinal reflex and bulbospinal sympathetic pathways. Transmission through spinal reflex pathways was secondarily enhanced after L-dopa. Pharmacological tests indicated mediation of these affects by monoamines. After antagonism or depletion of central 5-HT, L-dopa only enhanced transmission through both pathways. The results indicate that hypotension and other sympathoinhibitory effects of L-dopa are produced at the spinal level by release of 5-HT from terminals of bulbospinal 5-HT pathways that are inhibitory to sympathetic preganglionic neurons. The excitatory effects of L-dopa are apparently mediated by release of catecholamines from bulbospinal noradrenergic pathways that are excitatory.

Cardiovascular effects of dopamine after central administration into conscious cats

Dopamine (30 and 45 mug) administered intracerebroventricular (i.c.v.) to a group of 10 conscious normotensive cats caused dose-related increases in blood pressure and heart rate. In 4 of these animals the initial cardiovascular stimulant effects of i.c.v. dopamine were followed by hypotension and bradycardia. 2 alpha-Methyldopamine (30 and 45 mug i.c.v.) produced qualitatively similar responses to dopamine except that the cardiovascular stimulant effects were smaller and the secondary depressant effects somewhat more prolonged. 3 Both stimulant and depressant effects of i.c.v. dopamine and alpha-methyldopamine were greatly inhibited by autonomic ganglion blockade or by adrenergic neurone blockade. 4 The cardiovascular stimulant effects of both i.c.v. dopamine and i.c.v. alpha-methyldopamine were selectively inhibited by beta-adrenoceptor blocking agents whilst the cardiovascular depressant effects of these substances were abolished by the alpha-adrenoceptor blocker phentolamine or by the dopamine-beta-hydroxylase inhibitor disulfiram. 5 Haloperidol by either i.c.v. or the intravenous route abolished both cardiovascular stimulant and depressant effects of i.c.v. dopamine, whilst pimozide by either route inhibited only the cardiovascular stimulant effects. 6 In 2 cats, injection of dopamine into the cisterna magna produced predominantly depressant effects on the cardiovascular system except with a higher dose which induced biphasic responses.

Studies on the centrally mediated hypotensive activity of guanabenz

Prior studies demonstrated that guanabenz reduces systemic blood pressure by inhibiting central sympathetic outflow as well as by adrenergic neuron blockade. Potential mechanisms responsible for the reduction of efferent sympathetic activity were examined in the present series. Guanabenz failed to modify carotid sinus nerve activity in a perfused sinus preparation. It reduced sympathetic outflow, heart rate and blood pressure in debuffered cats indicating that its actions are not mediated primarily by baroreceptor mechanisms. alpha-Adrenergic blockade greatly attenuated the response suggesting that the central sympathoinhibitory effect of guanabenz results from alpha-adrenergic receptor activation. Only a high dose of the compound attenuated the increase in sympathetic nerve activity produced by stimulation of the posterior hypothalamus. These experiments lead to the overall conclusion that guanabenz acts primarily at sites which regulate the basal level of sympathetic outflow.

Central and peripheral contribution to the antihypertensive action of indoramin

Indoramin has been reported to reduce blood pressure in experimental animals and humans. The complex pharmacological profile of the compound suggests that it may also exert central actions. Effects on spontaneous sympathetic outflow and on sympathetic nerve and blood pressure responses to hypothalamic stimulation were examined in anesthetized cats in the present study. At a low dose (1 mg/kg) indoramin reduced blood pressure but did not significantly influence the level of efferent sympathetic nerve activity. A higher dose (5 mg/kg) lowered pressure further and inhibited activity in the splanchnic, cardiac and renal nerves indicating that reduced sympathetic outflow is a contributing factor to the hypotensive response at this dose. However, in contrast to other centrally acting antihypertensive agents, e.g., clonidine, indoramin did not inhibit the increase in sympathetic nerve activity produced by hypothalamic stimulation.